Patents Assigned to UREKA SARL
-
Patent number: 11285219Abstract: The present description relates to peptidomimetic foldamers, and their synthesis. In particular, the description provides peptide-amino urea hybrid peptidomimetic foldamers comprising an alpha amino acid peptide portion and an oligourea portion.Type: GrantFiled: January 16, 2020Date of Patent: March 29, 2022Assignees: UREKA SARL, Centre National de la Recherche Scientifique (CNRS)Inventors: Robert H. Zimmer, Gilles Guichard, Juliette Fremaux, Sebastien Goudreau, Claire Venin, Laura Mauran
-
Patent number: 11267861Abstract: The present description provides compositions and methods for producing therapeutic compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the present disclosure relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the present disclosure may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.Type: GrantFiled: April 19, 2017Date of Patent: March 8, 2022Assignee: UREKA SARLInventors: Robert H. Zimmer, Sebastien Goudreau, Gilles Guichard, Juliette Fremaux, Claire Venin, Laura Mauran
-
Patent number: 10889627Abstract: The present disclosure relates to a pro-drug peptide, or a salt thereof, having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism. The pro-drug peptide comprising the following structure: Z-pep, wherein: pep is the parent peptide or peptidomimetic; Z is a sequence of n amino acids, Z is cleaved in vivo releasing pep; n?2 amino acids. The present disclosure also relates to methods of making and using the pro-drug peptide of the present disclosure. For example, the present disclosure describes a pro-drug peptide that may be used to prevent, treat, or ameliorate at least one symptom of hypoglycemia or a hypoglycemia-related disease or disorder.Type: GrantFiled: June 29, 2018Date of Patent: January 12, 2021Assignee: UREKA SARLInventors: Robert H. Zimmer, Gilles Guichard, Juliette Fremaux, Claire Venin, Sebastien Goudreau
-
Patent number: 10414722Abstract: The present description provides oligourea catalysts, a polar helical oligomeric strands, and methods for catalyzing reactions with polar helical oligomeric strands and oligourea catalysts. In particular, the invention relates to a polar helical oligomeric strand of at least 4 residues selected from the formula (I) and which can be used as a catalyst.Type: GrantFiled: June 22, 2016Date of Patent: September 17, 2019Assignees: UREKA SARL, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Sebastien Goudreau, Gilles Guichard, Lucile Fischer, Arnaud Salaun, Vincent Diemer, Diane Becart
-
Patent number: 10398750Abstract: The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.Type: GrantFiled: August 21, 2014Date of Patent: September 3, 2019Assignees: UREKA SARL, Centre National De La Recherche Scientifique (CNRS)Inventors: Robert H. Zimmer, Gilles Guichard, Juliette Fremaux
-
Patent number: 10233213Abstract: The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the disclosure relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the disclosure may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.Type: GrantFiled: August 31, 2016Date of Patent: March 19, 2019Assignees: UREKA SARL, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Gilles Guichard, Gavin W. Collie, Karolina Pulka-Ziach, Caterina Maria Lombardo, Juliette Fremaux
-
Publication number: 20180244718Abstract: The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the disclosure relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the disclosure may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.Type: ApplicationFiled: August 31, 2016Publication date: August 30, 2018Applicants: UREKA SARL, Centre National De La Recherche Scientifique (CNRS)Inventors: Gilles Guichard, Gavin W. Colle, Karolina Pulka-ziach, Caterina Maria Lombardo, Juliette Fermaux